Navigation Links
Peregrine Pharmaceuticals Reports Financial Results for the First Quarter of Fiscal Year 2009
Date:9/9/2008

Total current assets 19,682,000 19,843,000

PROPERTY:

Leasehold improvements 669,000 669,000

Laboratory equipment 4,140,000 4,140,000

Furniture, fixtures and office equipment 919,000 919,000

5,728,000 5,728,000

Less accumulated depreciation and

amortization (3,803,000) (3,670,000)

Property, net 1,925,000 2,058,000

Other assets 1,201,000 1,156,000

TOTAL ASSETS $22,808,000 $23,057,000

PEREGRINE PHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS (continued)

JULY 31, APRIL 30,

2008 2008

Unaudited

LIABILITIES AND STOCKHOLDERS' EQUITY

CURRENT LIABILITIES:

Accounts payable $3,134,000 $2,060,000

Accrued clinical trial site fees 305,000 237,000

Accrued legal and accounting fees 210,000 450,000

Accrued royalties and license fees 151,000 222,000

Accrued payroll and related costs 955,000 1,084,000

Capital lease obligation, current

portion 22,000 22,000

Deferred revenue 4,021,000 2,196,000

Deferred government contract revenue 980,000 -

Customer deposits 1,898,000 838,000

Other current liabilities 336,000 331,000

Total current liabilities
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Peregrine Pharmaceuticals to Report First Quarter FY 2009 Financial Results
2. Peregrine Pharmaceuticals Receives Letter from NASDAQ Citing Failure to Regain Compliance with Minimum Bid Price Rule
3. Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2008
4. Peregrine Pharmaceuticals Awarded DTRA Contract Worth up to $44.4 Million to Develop Bavituximab for Viral Hemorrhagic Fevers
5. Peregrine Pharmaceuticals Presents Promising Phase I Data at ASCO and Provides Clinical Update on Its Phase II Bavituximab Breast Cancer Study
6. Peregrine Pharmaceuticals Reports Studies Published in Science Highlight Key Role of Phosphatidylserine (PS) in Viral Infections
7. Peregrine Pharmaceuticals Announces Four Upcoming Presentations at the American Association for Cancer Research 2008 Annual Meeting
8. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
9. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
10. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
11. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... ... 27, 2015 , ... Brady (NYSE:BRC), a global ... 3 Ways to GHS Labels . This video provides useful information on how ... by effectively labeling chemical containers. , “With the fourth and final deadline for ...
(Date:7/27/2015)... WORTH, Texas , July 27, 2015 ... Media Market by Type (Home-brew Media, Pre-formulated Media), by Application ... America , Europe , ... Forecast to 2019", The global biopreservation media market was valued ... to around $571.5 million by 2019, at a CAGR of ...
(Date:7/27/2015)... ... July 27, 2015 , ... Visual Assay was named as ... top 100 most innovative technologies and services of the past year. More than 70 ... Software/Services category. The winners will be announced at the 2015 R&D 100 Awards Dinner ...
(Date:7/24/2015)... San Diego, CA (PRWEB) , ... July 24, 2015 , ... ... Hospital & Referral Center in support of stem cell therapy training and clinical opportunities. ... offer this new opportunity to veterinarians in the San Diego area. Stem cell therapy ...
Breaking Biology Technology:Brady Releases “3 Roads to GHS Labels” Video 2Global Biopreservation Media Market to be Worth $571.5 Million by 2019 2Global Biopreservation Media Market to be Worth $571.5 Million by 2019 3Visual Assay® Named Finalist in 53rd Annual R&D 100 Awards 2VetStem Biopharma, proudly announces a new long term partnership with VCA Emergency Animal Hospital & Referral Center. 2VetStem Biopharma, proudly announces a new long term partnership with VCA Emergency Animal Hospital & Referral Center. 3
... Pharmos Corporation,(Nasdaq: PARS ) today reported results for ... net loss of $2.7 million, or $0.10 per share,for the ... million, or,$0.18 per share, in the second quarter 2007. Cash ... The decrease in net loss for the second quarter 2008 ...
... Mass., Aug. 7 Verenium Corporation,(Nasdaq: VRNM ... and a,pioneer in the development of high-performance specialty ... Vice President, will present at,the upcoming Canaccord Adams ... to begin at 10:30 a.m. ET on Thursday, ...
... New Launches Should Contribute Significantly in Second ... Inc. (NYSE: PRX ) today announced results for the,second ... Month Results, For the second quarter ended June 28, ... loss of $20.1 million, or $0.60 per diluted,share. This is ...
Cached Biology Technology:Pharmos Corporation Reports 2008 Second Quarter Results 2Pharmos Corporation Reports 2008 Second Quarter Results 3Pharmos Corporation Reports 2008 Second Quarter Results 4Pharmos Corporation Reports 2008 Second Quarter Results 5Verenium Corporation to Present at Canaccord Adams 28th Annual Global Growth Conference 2Verenium Corporation to Present at Canaccord Adams 28th Annual Global Growth Conference 3Par Pharmaceutical Reports Second Quarter 2008 Results 2Par Pharmaceutical Reports Second Quarter 2008 Results 3Par Pharmaceutical Reports Second Quarter 2008 Results 4Par Pharmaceutical Reports Second Quarter 2008 Results 5Par Pharmaceutical Reports Second Quarter 2008 Results 6Par Pharmaceutical Reports Second Quarter 2008 Results 7Par Pharmaceutical Reports Second Quarter 2008 Results 8
(Date:6/25/2015)... According to a new ... Area), Technology, Material (Optical Prism, Piezoelectric, Capacitive & ... Others) & Geography - Global Forecast to 2014 ... is expected to reach $14,500.07 Million by 2020, ... Browse 76 market Tables and 109 Figures spread ...
(Date:6/24/2015)... , June 24, 2015 This report provides ... the next six years. It contains an analysis of ... along with their impact from the short, medium, and ... discusses the industry, market, and technology trends that currently, ... need of concerned authorities to efficiently manage the increasing ...
(Date:6/23/2015)...   MedNet Solutions , an innovative SaaS-based ... of clinical research, is pleased to announce that ... company,s intuitive, flexible and affordable cloud-based eClinical technology ... Award by the American Business Awards (SM) ... The American Business Awards are considered the nation,s ...
Breaking Biology News(10 mins):Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4Automatic Identification System Market by Class, by Platform, by Application and by Geography - Global Forecasts & Analysis to 2014 - 2020 2MedNet Solutions' iMedNet eClinical Wins Silver Stevie Award 2
... Reinforcing its commitment to supporting high-quality cancer ... Foundation have again partnered with the American Association ... funding opportunities, the Landon Foundation-AACR INNOVATOR Award for ... Award for International Collaboration in Cancer Research. ...
... boost our understanding of the fragile marine environment, the ... for Environment, Fisheries & Aquaculture Science (Cefas) are launching ... existing collaboration between the two institutions and establish exciting ... climate change on the marine environment will influence much ...
... 10, 2008 Uncovering a rare, two-billion-year-old window into the ... have found our planets geological history is more complex than ... geosciences at UH, led a team of researchers in a ... new light on the mantle, the vast layer that lies ...
Cached Biology News:Landon Foundation-AACR INNOVATOR Awards 2Landon Foundation-AACR INNOVATOR Awards 3Landon Foundation-AACR INNOVATOR Awards 4New UEA-Cefas alliance launched 2Journey to the center of the earth: Discovery sheds light on mantle formation 2Journey to the center of the earth: Discovery sheds light on mantle formation 3
One-step, microplate or cuvet, turbidometric, linear detection range 0.096 mg/dL to 11.5 mg/dL. Procedure: 5 min....
Homo sapiens 4-aminobutyrate aminotransferase Antigen: Recombinant Protein...
Request Info...
...
Biology Products: